Salim S. Abdool Karim is a clinical infectious diseases epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment. He is CAPRISA Professor for Global Health in the Department of Epidemiology at the Mailman School of Public Health at Columbia University.  He is also Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA), Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal in Durban, South Africa and Adjunct Professor of Medicine at Weill Medical College of Cornell University.

His contributions to microbicides for HIV prevention spans two decades and culminated in the CAPRISA 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents which have been used in several HIV vaccine candidates and his clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients.

He is Chair of the UNAIDS Scientific Expert Panel, Chair of the WHO's HIV and Hepatitis Scientific and Technical Advisory Group and a member of the WHO HIV-TB Task Force. He is an elected Fellow of the World Academy of Sciences, the African Academy of Sciences, the Academy of Science in South Africa, the Royal Society of South Africa and the American Academy of Microbiology. He is a Foreign Associate Member of the US National Academy of Medicine.

He serves on the Boards of the New England Journal of Medicine, Lancet-Global Health, Lancet-HIV and the Journal of AIDS.

Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the next badge(s):